Quantum Biopharma Ltd. Class B Subordinate Voting Shares (QNTM)
QNTM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | QNTM on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001771885 |
Financials
No annual revenue filed since the period ending 2019-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Based on management's expectations of future net cash flows, management has applied judgement that there is no material uncertainties related to events or conditions that may cast substantial doubt on the Company's ability to continue as a going concern." | 20-F 2026-03-26 |
| Cash and burn | $1.9M cash; operating cash flow -$2.1M a quarter. | Report 2025-12-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-65 on 2024-08-15 | Source 2024-08-15 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-22 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MNP LLP, Mississauga, Canada | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | Not filed | -$8.2M | $1.9M | $1.3M | Needs four quarters | 20-F 2026-03-26 |
| FY 2024 2024-12-31 | Not filed | Not filed | -$6.9M | $6.0M | $619K | Needs four quarters | 20-F 2026-03-26 |
| FY 2023 2023-12-31 | Not filed | Not filed | -$10.8M | $2.8M | No debt tags | Needs four quarters | 20-F 2026-03-26 |
| FY 2022 2022-12-31 | Not filed | -$23.6M | -$28.3M | $17.0M | No debt tags | Needs four quarters | 20-F 2023-03-31 |
| FY 2021 2021-12-31 | Not filed | -$35.3M | -$20.7M | $35.3M | No debt tags | Needs four quarters | 20-F 2023-03-31 |
| FY 2020 2020-12-31 | Not filed | -$31.8M | -$19.1M | $17.5M | No debt tags | Needs four quarters | 20-F 2023-03-31 |
| FY 2019 2019-12-31 | Not filed | -$39.1M | -$13.7M | $6.0M | No debt tags | Needs four quarters | 40-F 2021-03-17 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.
Price moves
| Window | Return |
|---|---|
| 1 week | -23.5% |
| 1 month | -44.3% |
| 3 months | -50.2% |
| Year to date | -77.9% |
| 1 year | -79.1% |
| From 52-week high | -85.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OPTH | Optimi Health Corp. Common Shares | $2.15 | -4.44% | $12.3M |
| LSTA | Lisata Therapeutics Inc. | $1.09 | -9.92% | $11.8M |
| BIVI | BioVie Inc. | $1.08 | -4.42% | $11.6M |
| DARE | Dare Bioscience Inc. | $0.5842 | -11.13% | $11.5M |
| KYNB | Kyntra Bio Inc. | $3.20 | -8.31% | $13.0M |
| CMMB | Chemomab Therapeutics Ltd. American Depositary Share | $1.62 | +5.88% | $13.0M |
| ASBP | Aspire-Lakewood Holdings Inc. | $8.06 | -5.29% | $11.3M |
| RADX | Radiopharm Theranostics Limited | $0.7676 | +1.00% | $11.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier